These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. Bleske BE; Welage LS; Touchette MA; Edwards DJ; Rodman DP; Shea MJ Ther Drug Monit; 1994 Apr; 16(2):216-20. PubMed ID: 8009573 [TBL] [Abstract][Full Text] [Related]
84. Study on antihypertensive efficacy of slow-release verapamil: pharmacokinetic and noninvasive hemodynamic profile. Vulpis V; Seccia TM; Ricci S; Nazzaro P; Pirrelli A Cardiovasc Drugs Ther; 1993 Dec; 7(6):899-900. PubMed ID: 8011568 [No Abstract] [Full Text] [Related]
85. The influence of age on the pharmacokinetics of verapamil. Ahmed JH; Meredith PA; Elliott HL Pharmacol Res; 1991 Oct; 24(3):227-33. PubMed ID: 1956867 [TBL] [Abstract][Full Text] [Related]
86. Controlled-release formulations of propranolol and verapamil. Dunn J J Clin Pharmacol; 1987 Jan; 27(1):22-31. PubMed ID: 3316302 [TBL] [Abstract][Full Text] [Related]
87. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. McTavish D; Sorkin EM Drugs; 1989 Jul; 38(1):19-76. PubMed ID: 2670511 [TBL] [Abstract][Full Text] [Related]
88. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429 [TBL] [Abstract][Full Text] [Related]
89. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Jørgensen NP; Walstad RA Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615 [TBL] [Abstract][Full Text] [Related]
90. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Fuenmayor NT; Faggin BM; Cubeddu LX Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570 [TBL] [Abstract][Full Text] [Related]
92. The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil. Hosie J; Hosie G; Meredith PA J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S60-2. PubMed ID: 2475690 [TBL] [Abstract][Full Text] [Related]
93. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Muijsers RB; Curran MP; Perry CM Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112 [TBL] [Abstract][Full Text] [Related]
94. Studies on verapamil in the treatment of essential hypertension: a review. Midtbø K; Hals O; Lauve O; van der Meer J; Storstein L Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):165S-171S. PubMed ID: 3530299 [TBL] [Abstract][Full Text] [Related]